Article
Medicine, General & Internal
Jee H. Choe, Hisham Abdel-Azim, William Padula, Mohamed Abou-El-Enein
Summary: This study evaluated the cost-effectiveness of CAR-T cell therapies for relapsed or refractory DLBCL. The results showed that second-line axicabtagene ciloleucel and third-line or later tisagenlecleucel were cost-effective, but uncertainty remains.
Review
Hematology
Liat Shargian, Pia Raanani, Moshe Yeshurun, Anat Gafter-Gvili, Ronit Gurion
Summary: CAR-T therapy has superior outcomes and safety compared to standard second-line treatment in patients with relapsed or refractory LBCL.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Hematology
Mi Kwon, Gloria Iacoboni, Juan Luis Reguera, Lucia Lopez Corral, Rafael Hernani Morales, Valentin Ortiz-Maldonado, Manuel Guerreiro, Ana Carolina Caballero, Maria Luisa Guerra Dominguez, Jose Maria Sanchez Pina, Alberto Mussetti, Juan Manuel Sancho, Mariana Bastos-Oreiro, Eva Catala, Javier Delgado, Hugo Luzardo Henriquez, Jaime Sanz, Maria Calbacho, Rebeca Bailen, Cecilia Carpio, Jose Maria Ribera, Anna Sureda, Javier Briones, Juan Carlos Hernandez-Boluda, Nuria Martinez Cebrian, Jose Luis Diez Martin, Alejandro Martin, Pere Barba
Summary: This retrospective study evaluated the safety and efficacy of Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) in relapsed/refractory large B-cell lymphoma (LBCL) outside of clinical trials. The results showed that the real-world experience with these CAR-T cell therapies was comparable to the pivotal trial results.
Article
Hematology
Gilles Salles, Stephen J. Schuster, Martin Dreyling, Luca Fischer, John Kuruvilla, Piers E. M. Patten, Bastian von Tresckow, Sonali M. Smith, Ana Jimenez-Ubieto, Keith L. Davis, Carla Anjos, Jufen Chu, Jie Zhang, Chiara Lobetti Bodoni, Catherine Thieblemont, Nathan H. Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Yucai Wang, Brian K. Link
Summary: The ELARA trial demonstrates that tisagenlecleucel (tisa-cel) is highly effective in treating relapsed or refractory follicular lymphoma (r/r FL). Compared to usual care, tisa-cel showed significantly higher complete response rate, overall response rate, and improved survival outcomes at 12 months.
Article
Medicine, General & Internal
F. L. Locke, D. B. Miklos, C. A. Jacobson, M-A Perales, M-J Kersten, O. O. Oluwole, A. Ghobadi, A. P. Rapoport, J. McGuirk, J. M. Pagel, J. Munoz, U. Farooq, T. van Meerten, P. M. Reagan, A. Sureda, I. W. Flinn, P. Vandenberghe, K. W. Song, M. Dickinson, M. C. Minnema, P. A. Riedell, L. A. Leslie, S. Chaganti, Y. Yang, S. Filosto, J. Shah, M. Schupp, C. To, P. Cheng, L. Gordon, J. R. Westin
Summary: This international phase 3 trial showed that axicabtagene ciloleucel therapy significantly improved event-free survival and response in patients with early relapsed or refractory large B-cell lymphoma compared to standard care, despite the expected high-grade toxic effects.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, Jose Antonio Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andres Jose Maria Ferreri, Takanori Teshima, Piers E. M. Patten, Joseph P. McGuirk, Andreas L. Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thieblemont
Summary: Tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy, demonstrated a high complete response rate of 69.1% and overall response rate of 86.2% in adults with relapsed or refractory follicular lymphoma. Adverse events post-treatment primarily included cytokine release syndrome and neurological events, with no treatment-related deaths reported.
Article
Oncology
Dario Marino, Marco Pizzi, Iuliia Kotova, Ronny Schmidt, Christoph Schroeder, Vincenza Guzzardo, Ilaria Talli, Edoardo Peroni, Silvia Finotto, Greta Scapinello, Angelo Paolo Dei Tos, Francesco Piazza, Livio Trentin, Vittorina Zagonel, Erich Piovan
Summary: This study identifies two proteins that are important for predicting the survival of patients with diffuse large B-cell lymphoma (DLBCL). Additionally, the expression levels of one of these proteins can predict sensitivity to a specific death-inducing drug, suggesting personalized treatment options. The oncogenic function of ETV6 in DLBCL is also highlighted.
Article
Oncology
Guillaume Cartron, Christopher P. Fox, Fei Fei Liu, Ana Kostic, Jens Hasskarl, Daniel Li, Ashley Bonner, Yixie Zhang, David G. Maloney, John Kuruvilla
Summary: This study used a matching-adjusted indirect comparison to compare the efficacy and safety of lisocabtagene maraleucel (liso-cel) to tisagenlecleucel in the treatment of relapsed or refractory aggressive large B-cell lymphomas. The results showed that liso-cel had greater efficacy and comparable or better safety profile than tisagenlecleucel.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Christopher Parker, Fei Fei Liu, Kristen A. A. Deger, Conrado Franco-Villalobos, Irina Proskorovsky, Scott J. J. Keating, Sonja Sorensen
Summary: The objective of this study was to evaluate the cost-effectiveness of lisocabtagene maraleucel (liso-cel) versus other available CAR T-cell therapies. The study found that liso-cel was less costly and marginally more effective than axicabtagene ciloleucel (axi-cel) and had a higher cost-effectiveness compared to tisagenlecleucel (tisa-cel). The analysis concluded that liso-cel is a cost-effective option from a commercial US payer perspective.
ADVANCES IN THERAPY
(2023)
Article
Oncology
Gloria Iacoboni, Guillermo Villacampa, Nuria Martinez-Cibrian, Rebeca Bailen, Lucia Lopez Corral, Jose M. Sanchez, Manuel Guerreiro, Ana Carolina Caballero, Alberto Mussetti, Juan-Manuel Sancho, Rafael Hernani, Pau Abrisqueta, Carlos Solano, Anna Sureda, Javier Briones, Alejandro Martin Garcia-Sancho, Mi Kwon, Juan Luis Reguera-Ortega, Pere Barba
Summary: Tisagenlecleucel shows promising efficacy in treating R/R LBCL with a best ORR of 60% and CR of 32%, with a median response duration of 8.9 months. Treatment with tisa-cel in a European SOC setting demonstrates a manageable safety profile and durable complete responses for patients with LBCL.
Article
Oncology
Yucai Wang, Preetesh Jain, Frederick L. Locke, Matthew J. Maurer, Matthew J. Frank, Javier L. Munoz, Saurabh Dahiya, Amer M. Beitinjaneh, Miriam T. Jacobs, Joseph P. Mcguirk, Julie M. Vose, Andre Goy, Charalambos Andreadis, Brian T. Hill, Kathleen A. Dorritie, Olalekan O. Oluwole, Abhinav Deol, Jonas Paludo, Bijal Shah, Trent Wang, Rahul Banerjee, David B. Miklos, Aaron P. Rapoport, Lazaros Lekakis, Armin Ghobadi, Sattva S. Neelapu, Yi Lin, Michael L. Wang, Michael D. Jain
Summary: This study evaluated the efficacy and toxicity of Brexucabtagene autoleucel (brexu-cel) for relapsed/refractory mantle cell lymphoma (MCL) in the standard-of-care setting. The results showed that the efficacy and toxicity of brexu-cel were consistent with those reported in the ZUMA-2 trial. Tumor-intrinsic features of MCL, and possibly recent bendamustine exposure, may be associated with inferior efficacy outcomes.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Abi Vijenthira, John Kuruvilla, Michael Crump, Michael Jain, Anca Prica
Summary: Recent studies have shown that polatuzumab vedotin and CD19 chimeric antigen receptor T-cell therapy (CAR-T) can significantly improve the progression-free survival of patients with diffuse large B-cell lymphoma compared to standard of care. However, these strategies are costly and it is uncertain whether they are cost-effective compared to standard of care.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi, Pierre Sesques, Guillaume Manson, Guillaume Cartron, David Beauvais, Louise Roulin, Francois Xavier Gros, Marie Therese Rubio, Pierre Bories, Jacques Olivier Bay, Cristina Castilla Llorente, Sylvain Choquet, Rene-Olivier Casasnovas, Mohamad Mohty, Stephanie Guidez, Magalie Joris, Michael Loschi, Sylvain Carras, Julie Abraham, Adrien Chauchet, Laurianne Drieu La Rochelle, Benedicte Deau-Fischer, Olivier Hermine, Thomas Gastinne, Jean Jacques Tudesq, Elodie Gat, Florence Broussais, Catherine Thieblemont, Roch Houot, Franck Morschhauser
Summary: This study compared the efficacy and toxicity of Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL). The results showed that axi-cel had better overall response rate, complete response rate, progression-free survival, and overall survival compared to tisa-cel. However, axi-cel also had higher frequency of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome compared to tisa-cel.
Article
Medicine, General & Internal
Manali Kamdar, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, David G. Maloney, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Lara Stepan, Ken Ogasawara, Timothy Mack, Jeremy S. Abramson
Summary: This study shows that lisocabtagene maraleucel (liso-cel), an autologous, CD19-directed chimeric antigen receptor (CAR) T-cell therapy, is an effective second-line treatment option for patients with early relapsed or refractory large B-cell lymphoma (LBCL). Liso-cel significantly improved event-free survival compared to standard of care, with manageable safety.
Article
Oncology
Yu Yagi, Yusuke Kanemasa, Yuki Sasaki, Mina Sei, Takuma Matsuo, Kento Ishimine, Yudai Hayashi, Mano Mino, An Ohigashi, Yuka Morita, Taichi Tamura, Shohei Nakamura, Toshihiro Okuya, Takuya Shimizuguchi, Naoki Shingai, Takashi Toya, Hiroaki Shimizu, Yuho Najima, Takeshi Kobayashi, Kyoko Haraguchi, Noriko Doki, Yoshiki Okuyama, Tatsu Shimoyama
Summary: This study demonstrated that chemosensitivity remains a crucial factor in predicting survival outcomes following CAR T-cell therapy, irrespective of the administration timing. Moreover, both ASCT and CAR T-cell therapy are acceptable treatment options after the response to second-line salvage chemotherapy.
Letter
Hematology
Meletios A. Dimopoulos, Philippe Moreau, Bradley Augustson, Nelson Castro, Tomas Pika, Sosana Delimpasi, Javier De la Rubia, Angelo Maiolino, Tony Reiman, Joaquin Martinez-Lopez, Thomas Martin, Joseph Mikhael, Kwee Yong, Marie-Laure Risse, Gaelle Asset, Sylvia Marion, Roman Hajek
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Sabine Kayser, David Martinez-Cuadron, Maher Hanoun, Friedrich Stoelzel, Cristina Gil, H. Christian Reinhardt, Eliana Aguiar, Kerstin Schaefer-Eckart, Juan Miguel Bergua Burgues, Bjoern Steffen, Teresa Bernal, Stefan W. Krause, Rosalia Riaza, Christoph Schliemann, Jose Cervera, Martin Kaufmann, Laura Torres-Minana, Mathias Haenel, Evelyn Acuna-Cruz, Edgar Jost, Jesus Lorenzo Algarra, Martina Crysandt, Lars Fransecky, Javier Cornago-Navascues, Sabrina Kraus, Joaquin Martinez-Lopez, Hermann Einsele, Dirk Niemann, Andreas Neubauer, Ruth Seggewiss-Bernhardt, Sebastian Scholl, Stefan A. Klein, Christoph Schmid, Markus Schaich, Martin Schmidt-Hieber, Sven Zukunft, Anthony D. Ho, Uwe Platzbecker, Claudia D. Baldus, Carsten Mueller-Tidow, Christian Thiede, Martin Bornhaeuser, Hubert Serve, Mark J. Levis, Pau Montesinos, Christoph Roellig, Richard F. Schlenk
Summary: This retrospective study analyzed 125 patients with acute myeloid leukemia and trisomy 4. Among them, 22% had trisomy 4 as the sole abnormality, while the remaining 78% had additional abnormalities. Patients with trisomy 4 as their sole abnormality had a high complete remission rate, but allogeneic hematopoietic cell transplantation did not improve overall survival.
Review
Immunology
Matteo Perrino, Fabio De Vincenzo, Nadia Cordua, Federica Borea, Marta Aliprandi, Armando Santoro, Paolo Andrea Zucali
Summary: Malignant mesothelioma (MM) is a rare and aggressive cancer with a poor prognosis. Platinum and pemetrexed chemotherapy is currently the standard treatment for unresectable disease, but there is a lack of approved treatments for subsequent lines. Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has shown promising results in both first line and second-third line settings for MM. However, there is a need for reliable biomarkers to improve patient selection, and various factors including histological subtype, PD-L1 expression, and tumor mutational burden have been studied with inconclusive results. Further research is needed to identify predictive biomarkers for immunotherapy in MM.
FRONTIERS IN IMMUNOLOGY
(2023)
Letter
Hematology
Armando Santoro, Alison J. Moskowitz, Silvia Ferrari, Carmelo Carlo-Stella, Julie Lisano, Stephen Francis, Rachael Wen, Alev Akyol, Kerry J. Savage
Article
Cell Biology
Elizabeth J. Wiseman, Jennifer I. Moss, James Atkinson, Hana Baakza, Emily Hayes, Sophie E. Willis, Paul M. Waring, Jaime Rodriguez Canales, Gemma N. Jones
Summary: Phosphorylated biomarkers are important for understanding drug mechanisms and dose selection in clinical trials, especially for protein kinase-targeting drugs like DNA-damage-response (DDR) inhibitors. However, the tissue fixation conditions for preserving DDR-specific phospho-biomarkers have not been explored. This study found that immediate formalin submersion and room temperature fixation for 24 hours are crucial steps for preserving DDR phosphorylated biomarkers.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
(2023)
Article
Pathology
J. Lynn Fink, Binny Jaradi, Nathan Stone, Lisa Anderson, Paul J. Leo, Mhairi Marshall, Jonathan Ellis, Paul M. Waring, Kenneth O'Byrne
Summary: Identification of somatic variants in cancer using high-throughput sequencing is common in clinical practice due to their predictive value for targeted therapies. SLIMamp technology, incorporated into commercially available cancer next-generation sequencing testing kits, claims to be able to analyze challenging tissue samples with low tumor purity, poor-quality DNA, and/or low-input DNA. This study aimed to substantiate this claim using the oncoReveal Solid Tumor Panel.
JOURNAL OF MOLECULAR DIAGNOSTICS
(2023)
Article
Medicine, General & Internal
Flavia Jacobs, Elisa Agostinetto, Alessandra Solferino, Rosalba Torrisi, Giovanna Masci, Armando Santoro, Rita De Sanctis
Summary: In real-world trials, the incidence of abemaciclib-induced diarrhea was higher than that reported in clinical trials. Diarrhea occurred in 92% of patients, with 17% experiencing grade >= 3 diarrhea. Supportive care was effective in managing diarrhea in 58% of patients, reducing the need for dose reduction or treatment discontinuation. The implementation of guideline-based supportive care is crucial in managing this toxicity.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Natalia Buenache, Andrea Sanchez-delaCruz, Isabel Cuenca, Alicia Gimenez, Laura Moreno, Joaquin Martinez-Lopez, Juan Manuel Rosa-Rosa
Summary: Despite improvements in patient outcomes using targeted anti-myeloma agents, multiple myeloma remains largely incurable. We used targeted capture hybridization DNA sequencing (tchDNA-Seq) technology to find new biomarkers for patient stratification and treatment outcomes prediction. These potential biomarkers could guide targeted and risk-adapted therapeutic approaches for multiple myeloma patients at different disease stages.
Article
Oncology
Laura Urwanisch, Michael Stefan Unger, Helene Sieberer, Hieu-Hoa Dang, Theresa Neuper, Christof Regl, Julia Vetter, Susanne Schaller, Stephan M. Winkler, Emanuela Kerschbamer, Christian X. Weichenberger, Peter W. Krenn, Michela Luciano, Lisa Pleyer, Richard Greil, Christian G. Huber, Fritz Aberger, Jutta Horejs-Hoeck
Summary: Epigenetic alterations play a significant role in cancer development, and the reversible nature of epigenetic changes makes them attractive targets for therapy. In this study, the authors investigated the expression of HDAC genes in AML patients and cell lines, and the effects of the HDAC inhibitor TMP269 on AML cells. They found significant overexpression of various HDACs in AML and observed that TMP269 treatment had effects on the proteome and growth of AML cells. Additionally, they demonstrated that the combination of TMP269 and venetoclax resulted in enhanced cell apoptosis. These findings highlight the potential of TMP269 as a therapeutic compound for AML.
Article
Oncology
Joaquin Martinez-Lopez, Javier De la Cruz, Rodrigo Gil-Manso, Adrian Alegre, Javier Ortiz, Pilar Llamas, Yolanda Martinez, Jose-Angel Hernandez-Rivas, Isabel Gonzalez-Gascon, Celina Benavente, Pablo Estival Monteliu, Victor Jimenez-Yuste, Miguel Canales, Mariana Bastos, Mi Kwon, Susana Valenciano, Marta Callejas-Charavia, Javier Lopez-Jimenez, Pilar Herrera, Rafael Duarte, Lucia Nunez Martin-Buitrago, Pedro Sanchez Godoy, Cristina Jacome Yerovi, Pilar Martinez-Barranco, Maria Garcia Roa, Cristian Escolano Escobar, Arturo Matilla, Belen Rosado Sierra, Maria Concepcion Alaez-Uson, Keina Quiroz-Cervantes, Carmen Martinez-Chamorro, Jaime Perez-Oteyza, Rafael Martos-Martinez, Regina Herraez, Clara Gonzalez-Santillana, Juan Francisco Del Campo, Arancha Alonso, Adolfo de la Fuente, Adriana Pascual, Rosalia Bustelos-Rodriguez, Ana Sebrango, Elena Ruiz, Eriel Alexis Marcheco-Pupo, Carlos Grande, Angel Cedillo, Carlos Lumbreras, Andres Arroyo Barea, Jose Manuel Casas-Rojo, Maria Calbacho, Jose Luis Diez-Martin, Julio Garcia-Suarez
Summary: This study evaluated the severity and survival of unvaccinated patients with hematological malignancies and COVID-19, compared to non-cancer patients. The 30-day mortality rate was 32.7%, with higher mortality among certain patient groups. The mortality rates in hematologic malignancy patients did not decrease like in non-cancer patients. Additionally, 27.3% of patients had post-COVID-19 conditions.
Article
Hematology
Adrian Minson, Nada Hamad, Pietro Di Ciaccio, Dipti Talaulikar, Matthew Ku, Sumita Ratnasingam, Chan Cheah, Costas K. Yannakou, Mark Bishton, Zi Yun Ng, Shivam Agrawal, Andrew Mcquillan, Anna Johnston, Emily Choong, Kimberly Wong, James Mcquillan, Ashley Beekman, Eliza Hawkes, Michael Dickinson
Summary: This study analyzed the treatment outcomes of 389 patients with mantle cell lymphoma and found that the rate of lymphoma-related death increased after each treatment line. Older age at diagnosis and early relapse after induction therapy were associated with a higher risk of death after second-line treatment. The results of this study support the exploration of novel therapies in earlier treatment lines.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Valentina Dapra, Marco Airoldi, Michela Bartolini, Roberta Fazio, Giuseppe Mondello, Maria Chiara Tronconi, Maria Giuseppina Prete, Giuseppe D'Agostino, Caterina Foppa, Antonino Spinelli, Alberto Puccini, Armando Santoro
Summary: Recently, there has been a significant shift in the therapeutic landscape of locally advanced rectal cancer (LARC) with the increasing adoption of total neoadjuvant treatment (TNT). This comprehensive approach involves administering chemotherapy and radiation therapy prior to surgery, followed by optional adjuvant chemotherapy. To provide the optimal tailored treatment regimen for patients, collaboration among healthcare professionals from various specialties is crucial. This review aims to provide insights into the current state of TNT for LARC and emerging strategies for future research and clinical practice, such as circulating tumor DNA, immunotherapy in mismatch repair-deficient tumors, and nonoperative management.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Alexia Francesca Bertuzzi, Maria Susanna Grimaudo, Alice Laffi, Laura Giordano, Nicolo Gennaro, Umberto Cariboni, Licia Vanessa Siracusano, Vittorio Quagliuolo, Piergiuseppe Colombo, D'Orazio Federico, Salvatore Lorenzo Renne, Cristina Specchia, Ferdinando Cananzi, Andrea Marrari, Pierina Navarria, Primo Andrea Daolio, Stefano Bastoni, Armando Santoro
Summary: This retrospective study aimed to investigate the clinicopathological characteristics and clinical outcomes of AYA sarcomas. The results showed that soft tissue sarcomas were more common in AYA patients and those aged under 25 had a poorer prognosis. The study also found no significant association between diagnostic delay and patient survival and progression-free survival.
Article
Hematology
Stephen M. Ansell, Paul J. Brockelmann, Gottfried von Keudell, Hun Ju Lee, Armando Santoro, Pier Luigi Zinzani, Graham P. Collins, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trneny, Mariano Provencio, Ulrich Jaeger, Wolfgang Willenbacher, Rachael Wen, Alev Akyol, Joanna Mikita-Geoffroy, Margaret A. Shipp, Andreas Engert, Philippe Armand
Summary: This study demonstrates that nivolumab provides frequent and durable responses in patients with relapsed/refractory classical Hodgkin lymphoma after autologous hematopoietic cell transplantation failure. Results suggest that treatment can be discontinued after persistent complete remission and resumed upon disease progression.
Meeting Abstract
Oncology
K. Wimmer, D. Hlauschek, M. Balic, G. Pfeiler, S. Strobl-Kacerovsky, R. Greil, C. F. Singer, S. Halper, G. Steger, C. Suppan, S. P. Gampenrieder, R. Helfgott, D. Egle, M. Filipits, R. Jakesz, L. Soelkner, C. Fesl, M. Gnant, F. Fitzal